Komori
OncoTherapy Science (4564) · InitiativeRestated

Research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease

First written in FY2021-Q2. 6 of 7 entries say "Restated". Latest entry: FY2026-H1.

7entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q2 – FY2026-H12020: 12021: 220212022: 220222023: 120232024: 020242025: 12025
Same theme, other companies
Joint research on a COVID-19 preventive vaccine using peptide technologyA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「In addition, the Company is conducting research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  2. FY2023-Q3RestatedAnnual report

    「In addition, the Company has begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  3. FY2023-Q1RestatedAnnual report

    「In addition, the Company has begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  4. FY2022-Q3RestatedAnnual report

    「In addition, the Company has begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  5. FY2022-Q1RestatedAnnual report

    「In addition, the Company has begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  6. FY2021-Q3RestatedAnnual report

    「In addition, the Company has begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease.」

    The Company continues research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease.
  7. FY2021-Q2First statedAnnual report

    「In addition, as of the date of filing, the Company had begun research and development of a peptide vaccine aimed at controlling infection with COVID-19 and preventing severe disease, and had completed a patent application for a COVID-19 peptide vaccine candidate.」

    The Company disclosed for the first time that it had begun research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease, and had completed a patent application for a vaccine candidate.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Research and development of a peptide vaccine aimed at controlling COVID-19 infection and preventing severe disease | OncoTherapy Science,Inc. (4564) | Komori